Floatz logo

68Ga-NNS309

HR+/HER2- Ductal Breast Cancer (BC)

Novartis PharmaceuticalsPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the HR+/HER2- Ductal Breast Cancer (BC) cohort.

Asset / SponsorPhaseRating
Carboplatin
GBG Forschungs GmbH
Phase 3BBB
Letrozole
University of Washington
Phase 4BBB
Cyclophosphamide
UMC Utrecht
Phase 3BB
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
GBG Forschungs GmbH
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
RenJi Hospital
Phase 3BB

View all 35 →

Same molecule, other indications

68Ga-NNS309 is also rated in:

pancreatic ductal adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →
invasive lobular breast carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
breast carcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →